Tarpeyo
Named-patient access overview. Tarpeyo is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Tarpeyo (budesonide delayed-release) is a targeted-release oral corticosteroid developed by Calliditas Therapeutics, formulated to deliver budesonide to the distal ileum where IgA-producing immune cells originate. The US Food and Drug Administration granted accelerated approval in December 2021 and converted to full approval in December 2023 for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression, generally defined as a urine protein-to-creatinine ratio of 1.5 g/g or higher. Tarpeyo is given orally as 16 mg once daily, taken in the morning at least one hour before a meal, for a nine-month treatment course, followed by a taper to 8 mg once daily for the final two weeks. The medicine is prescribed and monitored by nephrology in an outpatient setting with attention to standard corticosteroid-class precautions.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Tarpeyo
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Tarpeyo is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Tarpeyo in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Tarpeyo
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.